Selva Therapeutics, Inc.
Selva Therapeutics is a privately held biotechnology company dedicated to developing therapeutics for infectious diseases. Their lead compound, SLV213, is a broad-spectrum antiviral drug candidate with activity against SARS-CoV-2, Ebola, Nipah, and other viruses. The company focuses on rapid development of treatments for COVID-19 and other life-threatening infectious diseases, aiming to bring valuable therapies to the market.
Industries
Nr. of Employees
small (1-50)
Selva Therapeutics, Inc.
Products
SLV213
An investigational orally bioavailable small-molecule inhibitor of host cysteine proteases (cathepsin L) developed to block viral spike activation and viral entry; advanced through preclinical studies and a completed Phase 1 clinical trial and positioned for Phase 2 outpatient studies.
SLV213
An investigational orally bioavailable small-molecule inhibitor of host cysteine proteases (cathepsin L) developed to block viral spike activation and viral entry; advanced through preclinical studies and a completed Phase 1 clinical trial and positioned for Phase 2 outpatient studies.
Expertise Areas
- Host-targeted antiviral development
- Small-molecule drug discovery
- Preclinical infectious disease models (including nonhuman primates)
- Clinical trial design and execution (Phase 1 and Phase 2 readiness)
Key Technologies
- Small-molecule cysteine protease inhibitors
- Host-directed antiviral mechanisms (cathepsin L inhibition)
- Cell-based viral infectivity assays
- Nonhuman primate infection models
News & Updates
Selva announced the first dosing in a Phase 1 clinical trial for SLV213, demonstrating safety and tolerability in healthy subjects, and showing potential for broad antiviral activity.
Selva presented preclinical data showing SLV213's efficacy against multiple SARS-CoV-2 variants, including Omicron, Delta, and original strains, with potential activity against future variants.
Selva announced the successful completion of a Phase 1 ascending dose clinical trial, demonstrating safety and lung protection in nonhuman primates, and readiness for Phase 2 trials.
Selva presented data showing SLV213's ability to protect lungs and enhance the efficacy of other antivirals like remdesivir and molnupiravir, supporting its potential as a broad antiviral.
Selva announced the first dosing in a Phase 1 clinical trial for SLV213, demonstrating safety and tolerability in healthy subjects, and showing potential for broad antiviral activity.
Selva presented preclinical data showing SLV213's efficacy against multiple SARS-CoV-2 variants, including Omicron, Delta, and original strains, with potential activity against future variants.
Selva announced the successful completion of a Phase 1 ascending dose clinical trial, demonstrating safety and lung protection in nonhuman primates, and readiness for Phase 2 trials.
Selva presented data showing SLV213's ability to protect lungs and enhance the efficacy of other antivirals like remdesivir and molnupiravir, supporting its potential as a broad antiviral.